All News

"Based on the definitions from the ASA and coverage rules for Medicare, the use of nitrous oxide for urology procedures is a noncovered service," write Jonathan Rubenstein, MD, and Mark Painter.

As 2023 comes to a close, we revisit some of this year’s top content on coding in urology.

As the year comes to a close, we revisit some of this year’s top content on kidney stones.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia in urology.

As the year comes to a close, we revisit some of this year’s top content on kidney cancer.

"We found that less than 5% of people with incontinence had received a surgical intervention for their incontinence within a year of the survey," says Giulia I. Lane, MD, MS.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

The study is set to begin in January 2024.

"This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” says Alicia K. Morgans, MD, MPH.

Investigators analyzed data from over 1300 patients undergoing treatment for prostate cancer at 5 hospitals.

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

"If the diversity and robust functional potential of the healthy human microbiome is repeatedly assaulted by the average Westernized lifestyle via antibiotic exposure, diet, and other environmental factors, kidney stone prevalence will continue to increase," the authors write.

Findings from the research showed that 68Ga-RM2 PET/MRI had an 85.2% sensitivity rate for diagnosing biochemical recurrence of prostate cancer.

The combination was explored in genomically defined metastatic renal cell carcinoma cohorts.

A response by the FDA is expected by February 2024.

"The Bladder CARE Assay's quantitative nature sets it apart from other tests," said Siamak Daneshmand, MD.

Overall, 177Lu-PNT2002 demonstrated a median radiographic progression-free survival of 9.5 months, compared with 6.0 months among patients who were treated with an ARPI.

The BLA submission is supported by findings from the phase 3 ZIRCON study, which demonstrated high specificity and sensitivity of the agent for PET/CT imaging of ccRCC.

Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

Eric J. Small, MD, is an international leader in prostate cancer research and has published more than 430 peer-reviewed articles.

Expert advice for physicians seeking new coverage.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.

Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

“What it brought up is the point that where the field seems to be going is incorporating the PET imaging and the MRI imaging, and maybe PET MRI,” says Michael S. Cookson, MD, MMHC, FACS.

The approval is supported by findings from the phase 3 LITESPARK-005 trial.